OncLive TV

Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC

October 27th 2023

Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.

Dr Garrido-Laguna on the Mechanism of Action of RMC-6236 in KRAS-Mutant PDAC

October 27th 2023

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

October 27th 2023

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.

Dr Choueiri on the Utility of Belzutifan/Cabozantinib in Advanced ccRCC

October 27th 2023

Toni K. Choueiri, MD, discusses findings from the phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma.

Dr Bilusic on Key Trials That Inform the Treatment of Patients With Urothelial Carcinoma

October 27th 2023

Marijo Bilusic, MD, PhD, discusses key trials in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Dr Girard on the Development of ADCs in Patients With NSCLC

October 27th 2023

Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.

Dr Mirza on the Use of Dostarlimab/Chemotherapy By Molecular Class in Endometrial Cancer

October 27th 2023

Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.

Dr Arbour on the Safety and Efficacy of RMC-6236 in KRAS-Mutant NSCLC

October 26th 2023

Kathryn C. Arbour, MD, discusses preliminary safety and efficacy data with the RAS inhibitor RMC-6236 in patients with KRAS-mutated non–small cell lung cancer.

Dr Berdeja on Ongoing and Planned Research Initiatives in Patients With Multiple Myeloma

October 26th 2023

Jesus Berdeja, MD, director, discusses ongoing and planned research initiatives in patients with multiple myeloma, specifically highlighting initiatives taking place at Tennessee Oncology.

Dr Hunter on the Ongoing Investigation into JAK Inhibitors in Myelofibrosis

October 26th 2023

Anthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.

Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial Carcinoma

October 26th 2023

Vivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.

Dr Patel on the Importance of Real-World Data in Lung Cancer Treatment

October 26th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care

October 26th 2023

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.

Dr Nakamura on the Association Between MRD Negativity and DFS in Resected CRC

October 25th 2023

Yoshiaki Nakamura, MD, PhD, discusses updated findings from an analysis of the association between circulating tumor DNA minimal residual disease status and disease-free survival in the GALAXY trial, an observational arm of the ongoing CIRCULATE-Japan trial in patients with resected colorectal cancer.

Dr Schmid on Key Efficacy Findings With Dato-DXd in Metastatic TNBC

October 25th 2023

Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.

Dr McKean on the ACTIVATE Study in Solid Tumors and PD-L1–Low Disease

October 25th 2023

Meredith McKean, MD, MPH, discusses the efficacy and safety of treatment with the anti-TGIT agent etigilimab and the PD-1 inhibitor nivolumab in patients with solid tumors and PD-L1-low disease.

Dr DiNardo on the FDA Approval of Ivosidenib in Relapsed/Refractory, IDH1+ MDS

October 24th 2023

Courtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.

Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer

October 23rd 2023

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.

Dr D'Abreo on HER2-Targeted Therapies in HER2+ Breast Cancer

October 23rd 2023

Dr Berdeja on the Evolving Use of CAR T-Cell Therapy in Multiple Myeloma

October 23rd 2023

Jesus Berdeja, MD, director, discusses the evolving guidelines regarding the use of CAR T-cell therapy in patients with multiple myeloma.